Catalyst
Slingshot members are tracking this event:
TG Therapeutics (TGTX) Completes Enrollment for Part 1 of Phase 2 Study of TG-1101 in Relapsing Forms of Multiple Sclerosis (RMS)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| TGTX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 11, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Enrollment, Phase 2, Tg-1101, Relapsing Forms Of Multiple Sclerosis
